The European Patent Office on Thursday handed a win to Moderna in a long-running patent battle with Pfizer and BioNTech over certain components of the mRNA vaccines authorized to fight Covid-19.
“We are pleased to announce that the European Patent Office decided to maintain the validity of Moderna’s EP949 patent, one of the key patents currently asserted against Pfizer and BioNTech in various European national courts,” Moderna said in an emailed statement. “While we anticipate that the opponents will appeal this decision, we appreciate the diligent review and thorough understanding of the scientific and legal issues demonstrated by the EPO Opposition Division during the oral proceedings.”
Thursday’s win for Moderna follows a loss last November as the EPO declared a different Moderna patent covering its Covid-19 vaccine invalid.
A Pfizer spokesperson told Endpoints News via email on Friday that the company “is disappointed about today’s 1st instance decision by the Opposition Division of the European Patent Office to maintain Moderna’s European patent EP3590949 B1. Pfizer will consider all legal options and may appeal this decision.”
Pfizer also said the patent proceedings have no impact on the company’s continuation in manufacturing and supplying its Covid-19 vaccine.
Listed as the inventors on the patent, which covers ribonucleic acids containing N1-methyl-pseudouracils and their uses, are Seagen senior director Jason Schrum, who served as a founding scientist at Moderna from 2010 to 2012; Antirna founder Suhaib Siddiqi, who served as director of chemistry at Moderna for five months in 2011; and uniQure medical director Kenechi Ejebe, who was a senior scientist at Moderna from 2011 to 2012, according to their LinkedIn profiles.
Moderna and Pfizer/BioNTech have also been battling over patents in the US, where last month a federal judge ruled that Moderna’s lawsuit against Pfizer and BioNTech should be put on hold while the US Patent and Trademark Office reviews petitions brought against two of the three Covid-19 vaccine-related patents that Moderna feels have been infringed.
Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Sangamo Therapeutics Secures Accelerated Approval Pathway for Gene Therapy in Fabry Disease
Sangamo Therapeutics has announced a major advancement in its gene therapy program for Fabry disease, as the U.S. FDA has provided a clear pathway for Accelerated Approval. This decision could potentially speed up approval timelines by three years, with a Biologics...
[2024/10/18] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
GSK sues Moderna over mRNA vaccine patents, seeks ‘reasonable royalty’
GSK on Tuesday unveiled a lawsuit filed against Moderna in Delaware federal court, alleging that its patented inventions provide the “foundation” for Moderna’s mRNA vaccine portfolio. GSK said it’s looking to recover “a reasonable royalty” for Moderna’s tens of...
Gene Therapy Automatically Converts Omega-6 to Omega-3 Fatty Acids in the Body
Shriners Children's Develops New Technology to Prevent Childhood Obesity ST. LOUIS, Oct. 16, 2024 /PRNewswire/ -- According to the Centers for Disease Control, nearly 20% of children and teens are considered obese. Research shows it can have a dramatic impact on a...
Related Services